Printer Friendly

InnoVet reports test results on IVET-629.

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Feb. 10, 1995--InnoVet Inc. (AMEX:IVT.EC), today said it has received results of a new study of its biological product IVET-629.

The results do not support immuno-stimulation as the product's mode of action. A mode-of-action study conducted at Iowa State University (ISU) was designed to show exactly how IVET-629 achieved successful results seen in animal trials, but instead has been unable to demonstrate how the product works. "The animal tests say it works, but now we're not sure how," said InnoVet CEO Ronald S. Brakke.

A 1993 study by researchers at the Ohio State University evaluated 20 horses suffering from lower respiratory disease. Of the 10 horses treated with IVET-629 and an antibiotic, nine recovered; of the 10 horses treated with an antibiotic and a placebo, only half recovered. The results of the Ohio study were consistent with results of three earlier efficacy trials conducted in Oklahoma and Arkansas, in which a total of 60 horses with respiratory disease were studied. Of the 30 horses treated with an antibiotic and IVET-629, 22 recovered. Of the 30 horses treated with an antibiotic and a placebo, only 10 recovered.

Brakke said the earlier clinical trials had been blind studies and demonstrated a positive effect of treatment with IVET-629, but the results of the mode-of-action study are forcing the company to re-evaluate IVET-629.

The new study, by Dr. James A. Roth and colleagues at ISU's College of Veterinary Science, used dexamethasone to create immune suppression effects in the test animals. IVET-629 was administered to evaluate its capability to stimulate the animals' suppressed immune systems. Results showed that IVET-629 prevented dexamethasone-induced decreases in hemoglobin concentration in the blood, and had a limited positive effect on two aspects of the treated animals' immune systems. However, use of IVET-629 showed no statistically significant effects for most measures of immune stimulant activity.

Brakke said that InnoVet is going to conduct biological activity tests on IVET-629 to further its efforts to obtain a license for the product.

Headquartered in West Palm Beach, InnoVet is a biotechnology company engaged in research, development and marketing of innovative products targeted primarily for the animal health care market.

CONTACT: InnoVet

Scott Cielewich, 407/687-8088

or

INFOCUS

Lori Kessler, 609/683-9055
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 10, 1995
Words:375
Previous Article:Marsh Supermarkets, Inc. reports third quarter results of operations.
Next Article:Misonix reports financial results.
Topics:


Related Articles
InnoVet reports third quarter results.
ImmuCell reports third-quarter, nine-months results.
Lost in Space.
Gateway answers call.
Reduced fluoroquinolone susceptibility in salmonella enterica serotypes in travelers returning from Southeast Asia. (Research).
A world of elders: how will the global community develop sustainable social structures for an aging population?
A roll-call of religious martyrs.
Basis of debt obligations in certain transactions.
IRAQ - Over 600,000 Killed.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters